Wells Fargo & Company Lowers Septerna (NASDAQ:SEPN) Price Target to $11.00

Septerna (NASDAQ:SEPN) had its price objective dropped by investment analysts at Wells Fargo & Company from $14.00 to $11.00 in a report issued on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 80.33% from the company’s current price.

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th.

Septerna Stock Performance

Shares of NASDAQ SEPN opened at $6.10 on Friday. The business has a 50-day simple moving average of $9.96. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.13 million. Research analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Insider Activity at Septerna

In other Septerna news, CFO Gil M. Labrucherie bought 10,500 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was acquired at an average price of $5.51 per share, with a total value of $57,855.00. Following the transaction, the chief financial officer now owns 10,500 shares in the company, valued at $57,855. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Alan Ezekowitz bought 7,491 shares of the stock in a transaction on Tuesday, March 4th. The shares were bought at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the purchase, the director now directly owns 24,911 shares in the company, valued at approximately $158,184.85. This trade represents a 43.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 74,346 shares of company stock valued at $439,670.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Septerna in the fourth quarter worth approximately $2,353,000. Woodline Partners LP purchased a new position in shares of Septerna in the 4th quarter worth $6,870,000. Zimmer Partners LP purchased a new stake in Septerna during the fourth quarter valued at $229,000. Soleus Capital Management L.P. bought a new position in Septerna in the fourth quarter valued at about $15,467,000. Finally, Nuveen Asset Management LLC purchased a new position in Septerna in the fourth quarter worth about $549,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.